Skip to main content

Table 9 Incremental cost-effectiveness ratio results

From: Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

ICER

Pemetrexed vs Docetaxel

ICER (QALYs)

€ 23967

ICER (LYG)

€ 17225

  1. ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year; LYG: life year gained
  2. The ICER for pemetrexed versus docetaxel demonstrates that pemetrexed is a cost-effective treatment compared to docetaxel.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us